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Protocol
========

1. Animal Handling
------------------

For the ChIn assay use 3 dpf larvae arising from group matings between homozygous double transgenic *cldnB::GFP/lysC::DsRED2* and *AB* (wild-type) fish. Collect embryos by natural spawning and raise them at 29 °C in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl~2~, 0.33 mM MgSO~4~, and 0.1% methylene blue, equilibrated to pH 7.0) in Petri dishes. It is essential to maintain a density of embryos not exceeding 50-70 per plate.

2. Larva Sorting
----------------

Check all larvae under a fluorescence stereoscope for fluorescent reporter expression, spontaneous inflammation and appropriate age related development.

3. Screening Medium Preparation (Always prepare fresh)
------------------------------------------------------

Prepare E3 medium without methylene blue supplemented with DMSO (1% final) and MS222 (0.05 g/l).

4. CuSO4 Preparation (Always prepare fresh)
-------------------------------------------

First weigh out CuSO~4~ (M~r~=159.6 g/mol) and prepare a 20 mM stock solution in dH~2~O. Prepare 120 μM CuSO~4~ working solution (from 20 mM stock solution) in E3/DMSO(1%)/MS-222. Protect CuSO~4~ solution from light.

5. 384-well Plate Preparation (Greiner 384 Well Microplate)
-----------------------------------------------------------

Pre-add 20 μl of E3/DMSO(1%)/MS-222 to each well with a reverse pipette. An increased pipette tip bore is required to handle the embryos carefully without inflicting any wounding; this is done by cutting the tip to a 2 mm bore. Transfer single larva in 74 μl of medium to each well (84 μl for untreated control). If necessary, orient larvae in a lateral position within the well using a flexible Eppendorf Microloader Pipette Tip (Eppendorf; 5242 956.003).

Conduct all following liquid handling steps with a robot liquid handling workstation to ensure simultaneous treatment of all larvae.

6. Drug Treatment
-----------------

Mix compounds in drug stock plate 5 times by pipetting up and down. Add 16 μl of 7.5X drug stock plate to each well and mix 5 times. Adjust tip position within wells to prevent injury of larvae and dispense the medium at 10 μl/s. Mix medium in wells 4 times to ensure homogenous distribution of the drug within the well.

7. Incubation
-------------

Incubate screening plate for 1 h at 29 °C covered with aluminum foil to protect compounds as well as CuSO~4~ from light.

8. Chemical Wounding
--------------------

Add 10 μl of 120 μM CuSO~4~ working solution to each well except to negative controls, mix 4 times and incubate again for 1 h at 29 °C.

9. Washing
----------

Remove and exchange 80 μl of medium from each well twice (in 20 μl steps) to remove compounds and CuSO~4~.

10. Image Acquisition
---------------------

Start image acquisition on an inverted automated microscope (i.e.: Olympus scan\^R) 90 minutes after initial copper treatment. Set initial z-level so that neuromasts from right and left posterior lateral line are visible. Image each well once per hour in the channels brightfield, Cy3 and GFP in 4 focal planes (50 μm distance) using a 4x objective (N.A. = 0.13).

Additional information on image and data processing are available upon request.

11. Image Processing
--------------------

1. Data sorting
---------------

Raw images are processed with our custom LabView software script. The first operation in the image processing pipeline is sorting of raw images from the microscope generated data folder by channel, well and time-point information.

2. Extended focus
-----------------

Subsequently the software creates extended focus images from 4 focal planes for each of the channels.

3. RGB-overlay
--------------

In a last step the extended focus images from the 3 channels are merged to result in a final RGB-overlay image.

4. Automated neuromast detection
--------------------------------

A pattern recognition tool (LabView Rapid IA prototyping tool) identifies neuromasts within the RGB overlay images and creates an empirically defined area of interest around the neuromasts.

5. Quantification
-----------------

Within the empirically defined area of interest surrounding injured neuromasts red fluorescent leukocytes (reflected as red pixels) are scored resulting in a primary readout of [p]{.ul}ercent [a]{.ul}rea [o]{.ul}ccupied by [l]{.ul}eukocytes (*Paol*). On average 95.27 ± 2.11% (FDA1) and 95.12 ± 1.56% (FDA2) of wells (larvae) have been detected properly and have subsequently been subjected to further data processing. The raw data output (*Paol* for each detected neuromast) is stored in a txt file and serves as the data input for the MATLAB scripts that process the raw data further.

12. Data Processing
-------------------

1. *iMaps*
----------

Assessing the success of individual experiments by graphical visualization of the raw data output *Paol* in a color code could be realized with so-called inflammation maps (*iMaps*) (**Figure 2**). Bright green reflects a high initial inflammatory index; black indicates no inflammation. This quick overview allows for rapid identification of failed experiments, which can then be excluded from further data analyses.

2. Averaging of controls
------------------------

Each experimental plate contains 320 compounds reflecting a single data point per compound and time-point as well as 32 positive and negative controls, respectively. The 32 control replicates are averaged and standard deviation is calculated. For the controls only data points within 2 standard deviations are included.

3. Normalization
----------------

Normalization is done by spreadsheet analysis. The average value of DMSO, being the negative control, is set to 0 and the highest averaged *Paol* for the copper control is set to 1, so that the maximum difference between the positive and negative control is set to 1. Each compound\'s *Paol* is linearly interpolated or extrapolated to the respective controls on the experimental plate.

4. Final read-out: Inflammatory index
-------------------------------------

After sufficient replicate experiments (i.e. 15) have been conducted, normalized raw data from replicate experiments are averaged, resulting in a final read-out - the inflammatory index. The initial inflammatory index of the copper control starts at 100% for time-point zero and correlates to image acquisition start time (90 minutes after initial copper treatment).

5. Monotonic exponential regression fitting
-------------------------------------------

Due to inflammation resolution over time we perform a monotonic exponential nonlinear regression fitting towards the initial inflammation by using - a~0~ is a measure for the initial response at t=0, a~1~ is related to the slope of the magnitude over time.

6. 2-D feature space plot (**Figure 4**)
----------------------------------------

To generate the feature space, a non-linear regression is applied and a cluster-analysis divides the feature space into characteristic regions, thus allowing automated identification of interesting candidates from different immune-modulatory categories (anti-inflammatory, anti-resolution, pro-inflammatory, pro-resolution). All compounds are displayed in the 2-D plot based on the parameters a~0~ and a~1~.

13. Data Handling and Storage
-----------------------------

Our data handling routines create webpages to visualize and represent such drug screens providing a quick overview of the image and data processing steps\' results, as well as a detailed view when requested by the user^10^. Soft links to other relevant heterogeneous biological and chemical databases are integrated as well to provide a valuable resource for comparative and novel studies^11^. By these routines, proper data standards and metainformation are set for long term storage of this data.

14. Representative Results
--------------------------

In a pilot screen we analyzed a library consisting of 640 FDA approved known bioactive compounds for effects on initiation, progression or resolution of a granulocytic inflammatory response. Based on the observed effects we classified 4 types of immune modulatory phenotypes that may be indicative of different modes of action: anti-inflammatory (1), anti-resolution (2), pro-inflammatory (3) and pro-resolution (4), which can be described with the parameters a~0~ and a~1~, that arise from a monotonic non-linear regression fitting (e^ao+alx^-)towards the initial inflammation. A~0~ represents the magnitude of the inflammatory response whereas a~1~ characterizes the slope of the curve and thus describes inflammation resolution. Displaying all compounds in a 2-D feature space plot (a~1~ vs. a~0~) allows for automated identification of hit candidates from the different immune modulatory categories (**Figure 3**).

45 out of 640 compounds exerted significant anti-inflammatory effect by reducing the initial inflammatory index to 50% or less. Within this category we found 6 compounds belonging to the pharmacological class of non-steroidal anti-inflammatory drugs (NSAIDs), confirming the validity of our approach. However, NSAIDs ranked not amongst the most potent anti-inflammatory drugs. Apart from the NSAIDs we found several additional pharmacological drug classes such as for example Angiotensin receptor blockers (ARBs), antibiotics and proton pump inhibitors.

7 compounds met the empirically defined threshold criteria for potential pro-resolution drugs.

18 drugs exerted a pro-inflammatory effect, resulting in exaggerated leukocyte recruitment to injured neuromasts compared to the positive controls.

Only 2 compounds prevented timely resolution of the inflammatory response.

The anti-inflammatory effect of several hit candidates (exemplary candidates from above mentioned pharmacological drug classes) from the pilot screen could be confirmed in a dose-dependent manner in subsequent secondary ChIn assays (data not shown). Retesting of 4 potential pro-resolution drugs did not confirm the indicated mode of action as exerted in the primary screen. 2 of the drugs had a slight anti-inflammatory potential at higher concentrations (20 μM). A third drug exhibited a marginal non-dose-dependent anti-inflammatory effect at drug concentrations ranging from 5 - 20 μM. The fourth drug had no effect on the inflammatory response at the concentrations tested.

**Figure 1. Workflow of the ChIn assay.**Individual compound transgenic *cldnB::GFP/lysC::DsRED2*larvae (3 dpf) are manually distributed in 384-well microtiter plates. Drugs are added simultaneously to each well using a Zephyr Compact Liquid Handling Workstation. Assay plates are then incubated for 1 h at 29 °C. Treatment with CuSO~4~- solution (10 μM final concentration) for 1 h inflicts the wounding and initiates an acute inflammatory response. Finally, copper solution and drugs are washed off and automated image acquisition is started (90 minutes after initial copper treatment).

**Figure 2. Overview picture of raw images.**The figure shows raw images of 4 focal planes (Z=0 - 3) at distances of 50 μm in the channels Cy3 (left) and GFP (right), respectively. Arrows (Z=1,2) indicate exemplary neuromasts, arrowheads (Z=1,2) point to clustered leukocytes around neuromasts.

**Figure 3. Inflammation Maps (iMaps).**The success of individual experiments can be assessed in *iMaps* reflecting the inflammatory response (raw data) in a color code: Bright green reflects a high initial inflammatory response; black indicates no inflammation. *iMaps*at timepoint 0 (left) and time-point 5 (right) clearly show whether an experiment should be included in further data processing. Copper controls (row 13 and 24) show up in varying shades of green, whereas DMSO control wells (row 1 and 12) appear in dark green or black. At time-point 5, inflammation is almost resolved in copper controls, now indicated in dark shades of green or black. [Click here to view larger figure](http://www.jove.com/files/ftp_upload/4203/4203fig3large.jpg).

**Figure 4. 2-D feature space plot of 320 compounds of an FDA approved library and their respective controls.**All compound wells can be displayed in a 2-D feature space plot based on the parameters a~0~ and a~1~, which arise from a non-linear regression fitting ( ) towards the initial inflammation. This feature space plot allows automated identification of interesting candidates belonging to one of the following 4 immune-modulatory categories that may be indicative of the drugs\' mode of action: anti-inflammatory (1), anti-resolution (2), pro-inflammatory (3) and pro-resolution (4). [Click here to view larger figure](http://www.jove.com/files/ftp_upload/4203/4203fig4large.jpg).

Discussion
==========

Here we present a fully automated high-throughput screening strategy enabling identification of immune-modulatory compounds in a whole animal context. Thus allowing monitoring of an acute inflammatory response *in vivo* and in real time.

We provide a protocol to apply zebrafish as a valuable model organism for drug discovery or drug repurposing efforts, since drug effects on leukocyte recruitment to wounds can be studied with relative ease in the context of a fully functional innate immune system. The unique advantage of our approach is the fact that chemical wounding renders manual larvae manipulation obsolete, thus permitting automation and screening in a high-throughput format.

Additionally, adverse or toxic drug effects as well as strong off-target effects can be easily assessed with the proposed set-up. The FDA approved library however did not contain any toxic compounds at the given screening concentrations. Nevertheless, we propose for apparent toxic compounds to compare the available dataset (e.g. immune modulatory phenotype, drug concentration) between members of the same pharmacological substance class present in the tested library. Toxic members of a substance family, that otherwise exerts a promising immune modulatory phenotype, could be retested at lower concentrations, if need be.

We have demonstrated the possibility of categorizing drugs automatically according to their exerted immune-modulatory effect. Drugs belonging to the category of anti-inflammatory compounds could be validated in independent experiments, most of the compounds exerting their effect in a dose-dependent manner. Four compounds identified as potential pro-resolution drugs could thus far not be confirmed as such. It also indicates that this particular immune modulatory category is difficult to describe, since no drugs solely affecting resolution have so far been described in literature. However, 3 of the 4 retested drugs showed an anti-inflammatory trend at higher molar concentrations. Optimizing the empirically defined threshold criteria should help to reduce the number of false-positives.

Furthermore, the presented technique offers the possibility to be utilized for the identification of mutations in genes affecting leukocyte migratory behavior^8^.

Concluding, the proposed method can facilitate and accelerate drug discovery or drug repurposing efforts by yielding potential new lead structures with readily available information on drug tolerance, toxicity, dosage as well as potential off-target effects. Therefore, serving as a simple, cost- and time-saving strategy at early stages of drug development.
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